NCT00248963

Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception

A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 Mg and Ethinyl Estradiol 20 Mg in a Continuous 28-Day Regimen for Oral Contraception Versus a Cyclic 21-Day Regimen Oral Contraceptive

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 600 (planned)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Female
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

To evaluate the contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen and to evaluate the safety compared to LNG 100 mg/EE 20 mg for 21 days followed by a 7-day hormone-free interval in a cyclic regimen.

Conditions

• Oral Contraceptive

Interventions

Type	Name	Description
DRUG	Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg

Timeline

• Completion: 2004-10-01
• First posted: 2005-11-04
• Last updated: 2006-05-19